ATE475645T1 - Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten - Google Patents
Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonistenInfo
- Publication number
- ATE475645T1 ATE475645T1 AT08735987T AT08735987T ATE475645T1 AT E475645 T1 ATE475645 T1 AT E475645T1 AT 08735987 T AT08735987 T AT 08735987T AT 08735987 T AT08735987 T AT 08735987T AT E475645 T1 ATE475645 T1 AT E475645T1
- Authority
- AT
- Austria
- Prior art keywords
- dual
- receptor antagonists
- pyrrolidine derivatives
- formula
- pyrrolidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07106666 | 2007-04-20 | ||
| PCT/EP2008/054261 WO2008128891A1 (en) | 2007-04-20 | 2008-04-09 | Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE475645T1 true ATE475645T1 (de) | 2010-08-15 |
Family
ID=39563424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08735987T ATE475645T1 (de) | 2007-04-20 | 2008-04-09 | Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7893062B2 (de) |
| EP (1) | EP2148857B1 (de) |
| JP (1) | JP5203449B2 (de) |
| KR (1) | KR101163847B1 (de) |
| CN (1) | CN101657418B (de) |
| AT (1) | ATE475645T1 (de) |
| AU (1) | AU2008240804B2 (de) |
| BR (1) | BRPI0810402A2 (de) |
| CA (1) | CA2682506C (de) |
| DE (1) | DE602008001983D1 (de) |
| ES (1) | ES2348002T3 (de) |
| IL (1) | IL201317A0 (de) |
| MX (1) | MX2009011051A (de) |
| WO (1) | WO2008128891A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48334E1 (en) | 2008-09-19 | 2020-12-01 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| JP2012505173A (ja) * | 2008-10-09 | 2012-03-01 | エフ．ホフマン−ラ ロシュ アーゲー | ピロリジンｎ−ベンジル誘導体 |
| US8022099B2 (en) | 2008-11-03 | 2011-09-20 | Hoffmann-La Roche Inc. | N-benzyl pyrrolidine derivatives |
| US8318759B2 (en) * | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
| US20110144081A1 (en) | 2009-12-15 | 2011-06-16 | Henner Knust | Pyrrolidine derivatives |
| US20110152233A1 (en) | 2009-12-18 | 2011-06-23 | Henner Knust | Pyrrolidine compounds |
| US8507535B2 (en) | 2010-07-07 | 2013-08-13 | Hoffmann-La Roche Inc. | Methyl-pyrrolidine ether derivatives |
| US8618303B2 (en) * | 2011-01-07 | 2013-12-31 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| CN103649076B (zh) * | 2011-05-13 | 2015-09-09 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
| JP6609253B2 (ja) * | 2014-08-06 | 2019-11-20 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| EP3574907B1 (de) | 2015-05-18 | 2023-08-23 | KaNDy Therapeutics Limited | Ein nk1/nk3-rezeptorantagonist zur behandlung von geschlechtshormonabhängigen erkrankungen |
| US10774091B2 (en) | 2018-03-14 | 2020-09-15 | KaNDy Therapeutics Limited | Soft gelatin capsule formulation |
| WO2019186358A1 (en) * | 2018-03-26 | 2019-10-03 | Novartis Ag | 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives |
| WO2020107189A1 (en) * | 2018-11-27 | 2020-06-04 | Legion Pharma Co. Ltd | Pyrrolidine compounds for the treatment of malaria |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU506399B2 (en) | 1975-12-30 | 1980-01-03 | Showa Denko Kabushiki Kaisha | 3-(2-aryl-2-propyl) ureas |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| CN1067683C (zh) | 1993-12-29 | 2001-06-27 | 默克·夏普-道姆公司 | 取代的吗啉衍生物及其作为治疗剂的用途 |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| EP1192952A3 (de) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst |
| US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
| ES2291891T3 (es) * | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
| US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| US20070270471A1 (en) * | 2004-08-09 | 2007-11-22 | Glaxo Group Limited | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine |
| JP2007008913A (ja) * | 2004-09-17 | 2007-01-18 | Tanabe Seiyaku Co Ltd | ピペリジン化合物およびその製法 |
| KR100939347B1 (ko) | 2005-07-20 | 2010-01-29 | (주)카이로드 | 광학적으로 순수한 (ｓ)-3-히드록시 피롤리딘의 제조방법 |
-
2008
- 2008-04-09 WO PCT/EP2008/054261 patent/WO2008128891A1/en not_active Ceased
- 2008-04-09 EP EP08735987A patent/EP2148857B1/de not_active Not-in-force
- 2008-04-09 AU AU2008240804A patent/AU2008240804B2/en not_active Ceased
- 2008-04-09 CA CA2682506A patent/CA2682506C/en not_active Expired - Fee Related
- 2008-04-09 CN CN2008800121653A patent/CN101657418B/zh not_active Expired - Fee Related
- 2008-04-09 BR BRPI0810402-6A2A patent/BRPI0810402A2/pt not_active IP Right Cessation
- 2008-04-09 KR KR1020097024085A patent/KR101163847B1/ko not_active Expired - Fee Related
- 2008-04-09 DE DE602008001983T patent/DE602008001983D1/de active Active
- 2008-04-09 ES ES08735987T patent/ES2348002T3/es active Active
- 2008-04-09 JP JP2010503460A patent/JP5203449B2/ja not_active Expired - Fee Related
- 2008-04-09 AT AT08735987T patent/ATE475645T1/de active
- 2008-04-09 MX MX2009011051A patent/MX2009011051A/es active IP Right Grant
- 2008-04-14 US US12/102,121 patent/US7893062B2/en not_active Expired - Fee Related
-
2009
- 2009-10-01 IL IL201317A patent/IL201317A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101657418A (zh) | 2010-02-24 |
| US20080275021A1 (en) | 2008-11-06 |
| DE602008001983D1 (de) | 2010-09-09 |
| EP2148857A1 (de) | 2010-02-03 |
| AU2008240804B2 (en) | 2013-02-21 |
| JP5203449B2 (ja) | 2013-06-05 |
| BRPI0810402A2 (pt) | 2014-11-04 |
| JP2010524880A (ja) | 2010-07-22 |
| EP2148857B1 (de) | 2010-07-28 |
| MX2009011051A (es) | 2009-10-30 |
| KR101163847B1 (ko) | 2012-07-09 |
| CA2682506A1 (en) | 2008-10-30 |
| IL201317A0 (en) | 2010-05-31 |
| ES2348002T3 (es) | 2010-11-26 |
| US7893062B2 (en) | 2011-02-22 |
| CN101657418B (zh) | 2012-05-30 |
| CA2682506C (en) | 2016-05-24 |
| WO2008128891A1 (en) | 2008-10-30 |
| KR20090130317A (ko) | 2009-12-22 |
| AU2008240804A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE475645T1 (de) | Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PL2164847T3 (pl) | Związki 3-azabicyklo[3.3.0]oktanowe | |
| MX2009003316A (es) | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. | |
| NO20083582L (no) | Pyridin-2-karboksamide derivater | |
| ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
| ATE446962T1 (de) | Thiazolopyridinon-derivate als mch- rezeptorantagonisten | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| EA201071234A1 (ru) | Производные изохинолинона в качестве nk3 антагонистов | |
| NO20093200L (no) | Tiazolidinderivater | |
| CY1111477T1 (el) | Θειενοπυριδινες ως αλλοστερικοι ενισχυτες του μ4 μουσκαρινικου υποδοχεα | |
| ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
| ATE478047T1 (de) | Indolderivate als viruzide | |
| NO20090779L (no) | 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister | |
| MX2010002584A (es) | Derivados de piperidina como agonistas de receptores muscarinicos. | |
| DE602007012313D1 (de) | Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate | |
| MX2009008323A (es) | Derivados heterociclicos como receptores muscarinicos m3. | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| BRPI0406704A (pt) | Antagonistas de 5ht~7~ e agonistas inversos | |
| ATE490958T1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
| ATE409179T1 (de) | Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten | |
| ATE542794T1 (de) | Pyrrolderivat oder salz davon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2148857 Country of ref document: EP |